White Paper: EMA’s 2017 FIH Guidelines. 5 years on and the Impact on Early Phase Clinical Studies
AC-Impact-of-EMAs-guidelines-on-FIH-studies-2022-White-Paper-Download
Articles related to clinical development, such as clinical development plan, etc are posted in this category.
AC-Impact-of-EMAs-guidelines-on-FIH-studies-2022-White-Paper-Download
Armstrong Clinical has now completed its first 2 years of operations. Although these two year have been during challenging time,…
Overcoming the Challenges Through Effective Clinical Study Design When developing novel therapies targeting rare diseases, a departure from classical development strategies…
We sit down with Haplomind founder Dr. Sonali Mohanty Quantius to understand more about Haplomind and its use in the…
Bradley Joblin from Armstrong Clinical has been invited to be the guest speaker at the AGM of HSP Research Foundation.…
Melbourne (Australia) - 4th August 2020: Armstrong Clinical, specialists in clinical development strategy, early phase clinical study design, pricing and regulatory strategy…
The aim for many biotech companies taking a discovery into clinical development will be to generate data from phase 1…
Important goals of pre-clinical drug development programs (in silico, in vivo, in vitro studies) include the formulation of precise estimates…
Clinical Trials in Australia The Australian clinical trial industry is large and growing fast. Roughly 1,360 new clinical trials were conducted in…